Konger, R.L.; Derr-Yellin, E.; Ermatov, N.; Ren, L.; Sahu, R.P.
The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism. Molecules 2019, 24, 2192.
https://doi.org/10.3390/molecules24112192
AMA Style
Konger RL, Derr-Yellin E, Ermatov N, Ren L, Sahu RP.
The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism. Molecules. 2019; 24(11):2192.
https://doi.org/10.3390/molecules24112192
Chicago/Turabian Style
Konger, Raymond L., Ethel Derr-Yellin, Nurmukambed Ermatov, Lu Ren, and Ravi P. Sahu.
2019. "The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism" Molecules 24, no. 11: 2192.
https://doi.org/10.3390/molecules24112192
APA Style
Konger, R. L., Derr-Yellin, E., Ermatov, N., Ren, L., & Sahu, R. P.
(2019). The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism. Molecules, 24(11), 2192.
https://doi.org/10.3390/molecules24112192